Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: rationale and design of the FORECAST trial

Mahmoudi, Michael, Nicholas, Zoe, Nuttall, Jacqui, Bresser, Moniek, Maishman, Tom, Berry, Colin, Hlatky, Mark A., Douglas, Pamela, Rajani, Ronak, Fox, Kim and Curzen, Nick (2019) Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: rationale and design of the FORECAST trial. Cardiovascular Revascularization Medicine. (doi:10.1016/j.carrev.2019.12.009).

Abstract

BACKGROUND: Fractional flow reserve measurement based on computed tomography (FFRCT) is a novel, well validated, non-invasive method for determining the presence and extent of coronary artery disease (CAD) combined with a physiological assessment of vessel-specific ischemia in patients with chest pain. Previous studies indicate that FFRCT reduces the uptake of invasive angiography that shows no significant CAD, without compromising patient safety. The clinical effectiveness and economic impact of using FFRCT instead of other tests in the initial evaluation of patients with stable chest pain has not been tested in a randomized trial.

METHODS: The FORECAST trial will randomise 1400 patients with stable chest pain to receive either FFRCT or routine clinical assessment as directed by the National Institute for Health and Care Excellence (NICE) CG95 guideline for Chest Pain of Recent Onset. The primary endpoint will be resource utilisation over the subsequent nine months, including non-invasive cardiac investigations, invasive coronary angiography, coronary revascularization, hospitalization for cardiac events, and the use of cardiac medications. Key pre-specified secondary endpoints will be major adverse cardiac events, angina severity, quality of life, patient satisfaction, time to definitive management plan, time to completion of initial evaluation, number of hospital attendances, and working days lost in patients who are in employment.

CONCLUSION: The FORECAST randomized trial will assess the clinical and economic outcomes of using FFRCT as the primary test to evaluate patients presenting with stable chest pain.

This record has no associated files available for download.

Contributors

Author: Michael Mahmoudi

Author: Nick Curzen

Download statistics